CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma

• Published in: Cancers 2024-07, Vol.16 (13), p.2437
• Main Authors: Issa, Issa Ismail, Due, Hanne, Brøndum, Rasmus Froberg, Veeravakaran, Vidthdyan, Haraldsdóttir, Hulda, Sylvester, Cathrine, Brogaard, Asta, Dhanjal, Soniya, Schmierer, Bernhard, Dybkær, Karen
• Format: Article
• Language: English
• Subjects: B-cell lymphoma; B-cell receptor; Cancer therapies; Cell cycle; Cell proliferation; Cell therapy; Chemotherapy; Cisplatin; Clinical trials; CRISPR; DNA damage; Drug dosages; Drug screening; Flow cytometry; Gene frequency; Genes; Genomes; Genomics; Immunosuppressive agents; Lymphocytes B; Lymphocytes T; Lymphoma; Medical prognosis; Mutation; Nucleotide excision repair; Patients; Platinum; RNA polymerase; Standard of care; Stem cell transplantation; Surveillance; Transplants & implants
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16132437

The recurrence of diffuse large B-cell lymphoma (DLBCL) has been observed in 40% of cases. The standard of care for refractory/relapsed DLBCL (RR-DLBCL) is platinum-based treatment prior to autologous stem cell transplantation; however, the prognosis for RR-DLBCL patients remains poor. Thus, to identify genes affecting the cisplatin response in DLBCL, cisplatin-based whole-genome CRISPR-Cas9 knockout screens were performed in this study. We discovered DNA damage response (DDR) pathways as enriched among identified sensitizing CRISPR-mediated gene knockouts. In line, the knockout of the nucleotide excision repair genes and sensitized DLBCL cells to platinum drugs irrespective of proliferation rate, thus documenting DDR as essential for cisplatin sensitivity in DLBCL. Functional analysis revealed that the loss of and increased DNA damage levels and altered cell cycle distribution. Interestingly, we also identified which is involved in B-cell receptor signaling, to affect cisplatin response. The knockout of increased cisplatin sensitivity in DLBCL cells, and combinatory drug screens revealed a synergistic effect of the BTK inhibitor, ibrutinib, with platinum drugs at low concentrations. Applying local and external DLBCL cohorts, we addressed the clinical relevance of the genes identified in the CRISPR screens. was among the most frequently mutated genes with a frequency of 3-5%, and and were also mutated, albeit at lower frequencies. Furthermore, 27-54% of diagnostic DLBCL samples had mutations in pathways that can sensitize cells to cisplatin. In conclusion, this study shows that and , in addition to , are essential for the response to platinum-based drugs in DLBCL.